Data-driven stock valuation

Avita Medical Inc (AVH) fair value: what the stock is really worth

We calculate from audited financials what Avita Medical Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

1. Compare price with fair valuebelow fair value = cheap, above = expensive
2. Check the quality50 and up solid, 75 and up strong
3. Watch it or check another stockalert when fair value or trend changes

Check any stock: type a name, ticker or ISIN

Healthcare · AU · Market cap A$190M (≈ $137M) · ISIN AU000000AVH4

At a glance

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (A$1.79). The favourable scenario is already priced in.
• Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range A$1.01 – A$6.14 · fair‑value band A$1.07 – A$1.79 · the A$2.83 price screens above the A$1.44 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Avita Medical Inc (AVH) currently trades at A$2.83, while our model-based Fair Value estimate is A$1.44, implying the stock looks roughly 97.0% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 3 models at a data quality of 85/100, which puts the evidence level at low.

Over the trailing twelve months, Avita Medical Inc generated revenue of A$72.3M at a net margin of −62.7%. Revenue grew 4.0% year over year. Net debt stands at A$38.0M. Fundamentals as of Jun 23, 2026

Scenario range: A$1.07 (bear) to A$1.79 (bull), the price of A$2.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades near its 52-week high and 183% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −31% fair-value upside, at −49%, AVH screens richer than that median.

Key figures & financial health

Quality Score breakdown

About the company

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.

Full company description

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Avita Medical Inc reported revenue of $74.1M in FY2025 versus $14.3M in FY2021, a compound +51.0%/yr. Reported net income was −$50.3M in FY2025.

AVH screens 97% overvalued. Compare with Abbott Laboratories, →

Peer Group

Medical Devices · 353 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Context: sector, industry, market

• Is the Health Care sector expensive or cheap?
• P/E, EV/EBITDA and margins by industry (reference tables)
• Valuation of the Australia market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions